Sanai Health Industry Group Past Earnings Performance
Past criteria checks 1/6
Sanai Health Industry Group has been growing earnings at an average annual rate of 24.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 13.5% per year. Sanai Health Industry Group's return on equity is 2.1%, and it has net margins of 13.4%.
Key information
24.7%
Earnings growth rate
24.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 13.5% |
| Return on equity | 2.1% |
| Net Margin | 13.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sanai Health Industry Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 98 | 13 | 23 | 0 |
| 31 Mar 24 | 110 | 16 | 19 | 0 |
| 31 Dec 23 | 122 | 19 | 14 | 0 |
| 30 Sep 23 | 152 | 28 | 19 | 0 |
| 30 Jun 23 | 181 | 37 | 24 | 0 |
| 31 Mar 23 | 179 | 33 | 28 | 0 |
| 31 Dec 22 | 176 | 29 | 32 | 0 |
| 30 Sep 22 | 136 | 20 | 28 | 0 |
| 30 Jun 22 | 96 | 11 | 24 | 0 |
| 31 Mar 22 | 82 | 10 | 20 | 0 |
| 31 Dec 21 | 68 | 9 | 16 | 0 |
| 30 Sep 21 | 79 | 10 | 14 | 0 |
| 30 Jun 21 | 90 | 10 | 12 | 0 |
| 31 Mar 21 | 106 | 8 | 13 | 0 |
| 31 Dec 20 | 121 | 6 | 15 | 0 |
| 30 Sep 20 | 118 | -15 | 19 | 0 |
| 30 Jun 20 | 114 | -36 | 22 | 0 |
| 31 Mar 20 | 98 | -37 | 24 | 0 |
| 31 Dec 19 | 82 | -39 | 26 | 0 |
| 30 Sep 19 | 55 | 92 | 6 | 0 |
| 30 Jun 19 | 35 | 7 | 19 | 0 |
| 31 Mar 19 | 46 | -4 | 24 | 0 |
| 31 Dec 18 | 58 | -14 | 29 | 0 |
| 30 Sep 18 | 69 | -455 | 55 | 0 |
| 30 Jun 18 | 75 | -681 | 49 | 0 |
| 31 Mar 18 | 69 | -916 | 47 | 0 |
| 31 Dec 17 | 63 | -1,152 | 44 | 0 |
| 30 Sep 17 | 96 | -941 | 62 | 0 |
| 30 Jun 17 | 130 | -731 | 79 | 0 |
| 31 Mar 17 | 196 | -563 | 89 | 0 |
| 31 Dec 16 | 263 | -396 | 98 | 0 |
| 30 Sep 16 | 373 | -275 | 92 | 0 |
| 30 Jun 16 | 483 | -153 | 86 | 0 |
| 31 Mar 16 | 519 | -56 | 91 | 0 |
| 31 Dec 15 | 556 | 41 | 97 | 0 |
| 30 Sep 15 | 558 | 18 | 100 | 0 |
| 30 Jun 15 | 561 | -6 | 104 | 0 |
| 31 Mar 15 | 555 | -25 | 108 | 0 |
| 31 Dec 14 | 550 | -44 | 112 | 0 |
| 30 Sep 14 | 544 | -27 | 118 | 0 |
| 30 Jun 14 | 537 | -10 | 124 | 0 |
| 31 Mar 14 | 535 | -7 | 128 | 0 |
| 31 Dec 13 | 532 | -4 | 132 | 0 |
Quality Earnings: WUP0 has a large one-off gain of CN¥18.7M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: WUP0's current net profit margins (13.4%) are lower than last year (20.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: WUP0 has become profitable over the past 5 years, growing earnings by 24.7% per year.
Accelerating Growth: WUP0's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: WUP0 had negative earnings growth (-64.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (28.7%).
Return on Equity
High ROE: WUP0's Return on Equity (2.1%) is considered low.